Impact of ⁶⁸Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer

The purpose of this prospective study was to estimate the effect of ⁶⁸Ga-labeled prostate-specific membrane antigen (PSMA)-11 PET on the intended management of patients with biochemically recurrent prostate cancer. Methods: Pre- and postimaging surveys were filled out by the referring providers for patients with biochemical recurrence who were imaged using ⁶⁸Ga-PSMA-11 PET. The inclusion criterion for this study was a prostate-specific antigen (PSA) doubling time of less than 12 mo after initial treatment (NCT02611882). Of the 150 consecutive patients imaged, 126 surveys were completed (84% response rate). The responses were categorized as major change, minor change, no change, or unknown change. Results: There were 103 patients (82%) with disease detected on ⁶⁸Ga-PSMA-11 PET. On the basis of the survey results, there were 67 patients (53.2%) withmajor changes in management and 8 patients (6.4%) with minor changes. The proportion of cases resulting in a change in management did not significantly differ by baseline PSA level. In patients with PSA levels below 0.2 ng/dL, 7 of 12 patients had disease detected on ⁶⁸Ga-PSMA-11 PET, 5 of whom had a major change in management. Conclusion: ⁶⁸Ga-PSMA-11 PET resulted in a major change in management in 53% of patients with biochemical recurrence. Further studies are warranted to investigate whether PSMA-based management strategies result in improved outcomes for patients.